FindTrial
Sign In

Colchicine 0.6 mg

DRUG11 trials

Sponsors

Population Health Research Institute, Gilead Sciences, Dyve Biosciences, Inc., University of British Columbia, HealthPartners Institute

Conditions

Acute Coronary SyndromeAortic StenosisAtrial FibrillationCovid19Decompensated Heart FailureGoutHeart FailureHeart Failure With Reduced Ejection Fraction

Phase 2

Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
CompletedNCT02063997
Gilead SciencesGout
Start: 2014-03-31End: 2015-01-31Updated: 2018-01-29
Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)
CompletedNCT04130204
Dyve Biosciences, Inc.Gout
Start: 2020-02-12End: 2021-05-21Updated: 2022-05-13
Impact of Colchicine and Low-dose Naltrexone on COVID-19
CompletedNCT04756128
HealthPartners InstituteCovid19
Start: 2021-01-25End: 2021-12-12Updated: 2023-07-25
Effect of Colchicine on the Progression of Aortic Valve Stenosis - a Pilot Study
RecruitingNCT05253794
Ottawa Heart Institute Research CorporationAortic Stenosis, Inflammation
Start: 2022-07-01End: 2026-09-30Target: 24Updated: 2024-12-11

Phase 3

Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study
CompletedNCT01985425
Population Health Research InstituteAtrial Fibrillation, Thoracic Surgery
Start: 2014-04-30End: 2015-09-30Updated: 2021-11-05
Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)
CompletedNCT04160117
Population Health Research InstituteAtrial Fibrillation, Recurrence
Start: 2020-01-14End: 2022-05-30Updated: 2024-09-19
Use of Colchicine to Decrease Atrial Fibrillation Recurrence After Ablation
NCT05459974
Stony Brook UniversityAtrial Fibrillation
Start: 2022-06-20End: 2024-11-30Target: 224Updated: 2022-07-15

Phase 4

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
RecruitingNCT04875702
Massachusetts General HospitalGout
Start: 2024-02-22End: 2028-10-31Target: 650Updated: 2025-09-25
Colchicine in Acutely Decompensated HFREF
RecruitingNCT06286423
University of VirginiaDecompensated Heart Failure, Heart Failure, Heart Failure With Reduced Ejection Fraction
Start: 2024-06-30End: 2028-06-30Target: 30Updated: 2024-05-08
MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
RecruitingNCT06543082
CHA UniversityAcute Coronary Syndrome
Start: 2024-08-05End: 2028-12-01Target: 490Updated: 2026-02-18

Unknown Phase

Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study
WithdrawnNCT04139655
University of British ColumbiaInfectious Complications, Major Adverse Cardiac Events, Myocardial Infarction +1
Start: 2020-09-01End: 2021-10-01Updated: 2021-11-19

Related Papers

Efficacy and safety of mono antiplatelet therapy with colchicine in acute coronary syndrome patients following percutaneous coronary intervention: rationale and design of the MACT II trial.
2025-10-27
C-reactive protein for prediction of atrial fibrillation recurrence after catheter ablation.
2020-09-2925 citations